Fasting and NAD⁺ really are connected, and the connection is almost never described accurately. Sirtuins — the enzymes both a fast and an NAD⁺ supplement are supposed to switch on — cannot work without NAD⁺, which is why the two get sold together. What has not been shown is that taking a precursor during a fast adds anything, in any human, at any dose.
This page walks the chain of reasoning link by link and marks where each one was measured. The underlying question — whether raising NAD⁺ does what it is marketed to do at all — is the evidence page, and it is worth reading first if you are new to this.
The biochemistry, stated precisely
Sirtuins are NAD⁺-dependent deacetylases and ADP-ribosyltransferases. They consume NAD⁺ as a substrate rather than merely being switched on by it, and they respond to cellular energy status — which is the reason they became the mechanistic centerpiece of caloric-restriction research. A 2026 review of that literature, defining caloric restriction as a 30 to 60% reduction in food intake without malnutrition, describes sirtuins as pivotal molecular mediators regulating gene expression, oxidative stress response, mitochondrial function and autophagy [1].
Every word of that is defensible, and almost all of the evidence behind it is cellular and rodent. That is normal for mechanism, and it is not a criticism. It becomes a problem only when a supplement page presents the mechanism as though the human outcome had been demonstrated, which is the recurring failure across this entire category.
What a fast actually did to NAD⁺ biology in people
The most direct human study is unusual and worth knowing in detail. Nineteen healthy volunteers each underwent a 24-hour fast and were then given a fixed-calorie meal, with blood drawn in both the fasted and the fed state and analyzed for activation of the NLRP3 inflammasome — a driver of metabolic inflammation. Individuals showed less NLRP3 inflammasome activation in the fasted state than after refeeding [2].
The same paper then did the thing that makes it useful here. Depleting SIRT3, a mitochondrial NAD⁺-dependent sirtuin, increased NLRP3 activation. Activating SIRT3 — genetically and pharmacologically — blunted NLRP3 activity in cultured cells and in leukocytes taken from healthy volunteers and from refed individuals, but not in leukocytes collected during the fast. A separate group of eight healthy volunteers was enrolled specifically to assess the effect of nicotinamide riboside on NLRP3 activation [2].
Read that middle finding carefully, because it is the opposite of the marketing logic. The intervention did its work in cells from people who had eaten, and did not in cells drawn while they were fasting. That is what you would expect if fasting had already engaged the pathway — and if it had, there was nothing left for the activator to add.
The autophagy claim, and the size of the study behind it
“Fasting triggers autophagy” is the sentence that sells the combination. The human evidence for it, in a fasting-schedule design, is a four-day randomized crossover in eleven overweight adults who ate between 8 a.m. and 2 p.m. on one schedule and 8 a.m. and 8 p.m. on the other.
Early time-restricted feeding lowered mean 24-hour glucose by 4 ± 1 mg/dl (p = 0.0003) and glycemic excursions by 12 ± 3 mg/dl (p = 0.001). In the morning before breakfast it raised ketones, cholesterol, and the expression of the stress-response and aging gene SIRT1 and the autophagy gene LC3A (all p < 0.04). In the evening it raised expression of MTOR, the nutrient-sensing protein that regulates cell growth (p = 0.007), and it altered the diurnal pattern of cortisol and several circadian clock genes [3].
That is a real result and the glucose numbers are solid. But the autophagy part is gene expression in whole blood cells, in eleven people, over four days — not autophagic flux measured in liver or muscle, and not an outcome anyone has followed. The authors say the schedule “may also increase autophagy”, which is the correct strength of claim and is stronger than anything published on the NAD⁺ side of the pairing.
What we searched for the combination, and when
In September 2026 we queried PubMed for randomized controlled trials and clinical trials of nicotinamide riboside or nicotinamide mononucleotide together with intermittent fasting, time-restricted eating or caloric restriction. The search returned two records, and neither is a trial of the combination — one is a leucine and resveratrol paper, the other the 24-hour fasting study described above. As a known-good control, the same query shape for metformin with caloric restriction returned a list of randomized trials, so the database was reachable and the query form works.
The combination has been tested — in mice. A 2025 study gave healthy Kunming mice time-restricted fasting with or without NMN and reported improved mitochondrial dynamics and respiratory function, greater endurance, limb strength and coordination, reduced post-exercise oxidative damage, and increased gut microbiota diversity [4]. The authors describe it as a theoretical framework for expanding the application of NMN and time-restricted fasting. It is a mouse study, it says so, and it is the entire published basis for the pairing.
Does a precursor break a fast?
Two different questions get asked with those words, and only one has an answer.
On calories, a capsule of NR or NMN contributes a negligible amount, which is true of most capsules and is not really the question. On whether it blunts the metabolic state a fast produces — the thing people are actually worried about — nothing has been measured. No published study has given an NAD⁺ precursor to fasting humans and tracked ketones, glucose, autophagy markers or sirtuin expression against a fasting control. Anyone telling you it is safe for your fast, or that it ruins it, is guessing in one direction or the other.
What this means if you are doing both
Fasting is free and has human trials behind it on glucose and inflammation. NAD⁺ precursors cost money and, pooled across fifteen randomized trials, produced no significant effect on body weight, BMI, fasting glucose, glycated hemoglobin, lipid profiles or systolic blood pressure [5]. If your reason for taking one is metabolic, the pooled answer is already in, and it is not encouraging — the weight-loss question is covered separately and lands in the same place.
The broader census agrees. A 2026 PRISMA-guided systematic review of 113 eligible studies, including 33 human intervention studies of which 28 were randomized, found consistent biochemical target engagement for oral NR and NMN alongside effects on functional, metabolic and vascular outcomes that were heterogeneous and often null [6].
So: fast if you want to, on the evidence for fasting. Take a precursor if you want to, on the evidence for precursors. Nothing published supports paying a premium for the combination, and if you do buy one, an oral capsule is where the trials are — not an infusion, which has no outcome trial of any description behind it.